Lutetium-177 PSMA Therapy ⭐Treatment in the Best Hospitals ⭐ Cost of Treatment by LU 177 psma ⭐ Bookinghealth

Lutetium-177 PSMA Therapy

Lutetium-177 PSMA Therapy ⭐ Popular treatment choice for cancer with metastatic ⭐ Choose best European hospitals with Lutetium-177 PSMA Therapy

Best hospitals and doctors for Lutetium-177 PSMA Therapy

Leading hospitals

Cost for treatment

Diagnosis of the prostate cancer with PSMA-PET
Neuroendocrine Tumors (NETs) Treatment with Lutetium-177-DOTATATE
Prostate Cancer Treatment with Lutetium-177 PSMA
According to the reputable Focus magazine, the Helios Hospital Berlin-Buch ranks among the top medical facilities in Germany! The clinic is proud of its rich history, which dates back over 100 years, as well as the status of a maximum care medical center with exceptionally high success treatment rates. The medical institution is
The Medicana International Istanbul Hospital is a modern medical institution, which provides patients with an individual approach, excellent health service and attentive care. The hospital is part of the largest Turkish network of the Medicana hospitals. Due to its long successful clinical activities, the network has won th
The Samsung Medical Center was founded in 1994 and soon won the reputation of a medical facility of presidential standards, which it still preserves today. The hospital has 40 departments, 10 specialized centers and a huge Cancer Center with 655 beds. The medical facility is equipped with advanced equipment (for example, a 32-ch
According to the reputable Focus magazine, the University Hospital Frankfurt am Main ranks among the top German medical facilities! The hospital was founded in 1914 and today is a well-known German medical facility, which combines rich traditions and scientific innovations. A medical team of more than 6,500 employees cares about
According to the Focus magazine, University Hospital Erlangen ranks among the best medical facilities in Germany! The hospital is one of the leading healthcare facilities in Bavaria and offers top-class medical care distinguished by the close intertwining of clinical activities with research and training of medical students. The
University Hospital Bonn

University Hospital Bonn

Overall rating9.2 / 10
According to the authoritative Focus magazine, the University Hospital Bonn ranks among the top ten medical facilities in Germany! The hospital was opened on January 1, 2001, although in fact it inherits the medical facility, which operated at the Faculty of Medicine of the University of Bonn. The hospital in Germany combin
According to the prestigious Focus magazine, the University Hospital Halle (Saale) ranks among the top German medical facilities! The history of the hospital has more than 300 years, and during this time it managed to earn an excellent reputation not only in Germany, but throughout the world. The hospital positions itself as a s
According to the authoritative Focus magazine, the University Hospital Duesseldorf ranks among the top Germany hospitals! The hospital is an excellent example of a combination of high-quality health care, research and teaching activities. With more than 50,000 inpatients and about 300,000 outpatients every year, the hospital is
University Hospital Jena

University Hospital Jena

Overall rating8.9 / 10
According to the prestigious Focus magazine, the University Hospital Jena regularly ranks among the top German medical facilities! The hospital has positioned itself as a multidisciplinary medical facility with a long history of more than 200 years. Since its foundation, the hospital has been constantly developing and modernizin
According to the Focus magazine in 2019, the University Hospital Würzburg ranks among the top national German hospitals! The hospital is one of the oldest medical facilities in Germany. The centuries-old traditions of first-class treatment are combined with the very latest achievements of modern evidence-based medicine and
According to the Focus magazine, the University Hospital Muenster ranks among the top German hospitals! The hospital belongs to the most prestigious medical institutions in Germany. The hospital is distinguished by a high professionalism of its doctors, state-of-the-art technological equipment and the availability of the most ad
According to the prestigious medical publication Focus, the University Hospital Tuebingen ranks among the top five German hospitals! The hospital was founded in 1805, therefore it is proud of its long history, unique experience, and outstanding achievements in the field of medical care, as well as research and teaching activitie
According to Focus magazine, the University Hospital Heidelberg ranks among the top five hospitals in Germany! The hospital is one of the most advanced and reputable medical institutions not only in Germany, but throughout Europe. There are more than 43 specialized departments and 13 medical institutes, which cover all fields of
University Hospital Essen

University Hospital Essen

Overall rating9.6 / 10
According to the authoritative Focus magazine the University Hospital Essen ranks among the top German hospitals! With 27 specialized departments and 24 institutes, the hospital in Germany is a maximum care medical facility. The hospital has 1,300 beds for inpatient treatment. A highly qualified medical team of more than 6,000 e
The University Hospital Saarland Homburg is the largest hospital in the city of Homburg and the most important medical facility in the region. The hospital, which currently has 30 specialized departments and 20 institutes, was founded in 1947 and operates on the basis of Saarland University. The hospital plays a leading role in
According to the authoritative Focus magazine, the Charite University Hospital Berlin occupies the first place in the rating of the top German medical facilities! The hospital is one of the largest and leading university medical complexes in Europe. The hospital in Germany provides modern diagnostics and treatment of patients, a
| from Booking Health GmbH

In terms of clinical course, prostate cancer is a relatively favorable condition. It can be treated even at the advanced stages. However, sooner or later the disease reaches that stage when chemotherapy is ineffective and various organs are affected by metastases. In such clinical situations, Lutetium-177 PSMA radionuclide therapy comes to the rescue. Being connected to the specific molecular carrier, Lutetium-177 reliably binds to malignant cells regardless of their localization. Local irradiation destroys metastatic foci and helps control the disease progression. Due to the unique mechanism of action, PSMA therapy with Lutetium-177 is effective in men who no longer respond to chemotherapy or hormonal therapy. During the last decades the procedure has become the therapy of choice in such patients regardless of their age.

This is a single intravenous infusion of Lutetium-177 solution. PSMA therapy with Lutetium-177 is indicated even if all other treatments have failed.

The radionuclide Lutetium-177 finds prostate cancer cells anywhere in the body and destroys them. This is especially important in bone metastases and metastases in internal organs. PSMA therapy with Lutetium-177 is performed at advanced cancer stages.

CountryAverage Lutetium PSMA therapy cost
Germany18,010 EUR
Turkey12,600 EUR
Austria12,000 EUR

The best hospitals for metastatic prostate cancer therapy are:

  • Helios Hospital Berlin-Buch
  • University Hospital Rechts der Isar Munich
  • University Hospital of Ludwig Maximilian University of Munich
  • University Hospital Frankfurt-am-Main
  • University Hospital Carl Gustav Carus Dresden


  1. European treatment options for advanced prostate cancer
  2. What is Lutetium therapy in Europe?
  3. Who is eligible for 177-Lutetium therapy in Europe?
  4. How does Lutetium-177-PSMA therapy in Europe work?
  5. Effectiveness of Lutetium-177-PSMA therapy in Europe
  6. What is the cost of Lutetium treatment in European hospitals?
  7. Treatment in European hospitals with Booking Health

European treatment options for advanced prostate cancer


Symptom relief is the main goal of treatment for patients with metastatic prostate cancer because an already disseminated pathology is usually incurable. Hormone-targeted therapy and chemotherapy are forms of first-line treatment for advanced prostate cancer. Even with numerous metastases, some radiation treatments can reduce the disease's symptoms. For more advanced stages of the disease, a combination of targeted radiation therapy and medication therapy is also useful. The aforementioned techniques may result in positive outcomes for a long time, but eventually the therapy will no longer be effective. In such cases, radioactive medicine that penetrates the bone tissue is used as a second-line treatment. As long as the malignant cells are localized only in the bone tissue, this method is secure and effective.

More innovative methods of treating cancer emerge every year. Oncologists now favor using medications that directly attack cancer cells. This therapeutic strategy has won numerous awards for effectiveness and safety. Neuroendocrine tumors, thyroid cancer, various forms of brain tumors, and prostate cancer can all be cured with targeted therapy.

So, the main topic of discussion is radionuclide therapy, a cutting-edge method that combines targeted radiation exposure with the special properties of nuclear fusion. Regrettably, such medical services can only be obtained abroad, including in hospitals in Europe. The basic idea behind radionuclide cancer therapy is to administer unique drugs that contain radionuclides. The radiation is targeted since these medications reach the damaged areas immediately (not affecting the entire body, but affecting the cancer foci). The primary tumor or metastases accumulate the drug that is injected during the radionuclide treatment. The neoplasm is destroyed after being exposed to radiation. The body as a whole, healthy structures nearby, and surrounding tissues are only minimally impacted.

Lutetium-177 PSMA therapy is a novel radionuclide therapy approach used to treat men with prostate cancer. The top oncologists in the world believe that such a strategy can treat cancer patients who have given up on finding a cure.

Because metastatic prostate cancer frequently results in clinical problems and relapses after treatment, treating it is challenging overall. According to the most recent findings of randomized trials, Lutetium-177-PSMA therapy, which is typically considered an alternative to conventional techniques, combined with traditional treatment protocols is a very effective therapy in severe cases of advanced prostate cancer when compared to hormonal therapy and chemotherapy.

What is Lutetium therapy in Europe?


The treatment involves the use of Lutetium-177 (Lu-177) labeled prostate-specific membrane antigen (PSMA), hence the name, PSMA therapy.

Radionuclide substance gives off radiation, but it is very short – only a few millimeters. This substance should destroy not only the primary tumor, but also metastatic foci of prostate cancer in bones and internal organs.

A radiopharmaceutical is administered to the patient intravenously. It accumulates only in tumor cells, while the healthy ones get just a minimal amount, so they are almost not damaged. With its action, Lu-177 PSMA therapy destroys all cancer cells throughout the body. As a result, the size of the primary tumor lesion is significantly reduced and most metastases disappear.

Who is eligible for 177-Lutetium therapy in Europe?


Lutetium-177 PSMA therapy is the targeted treatment that is used in the combination therapeutic schemes for advanced prostate cancer. It is prescribed in the presence of multiple distant metastases. Indeed, the main advantage of the method is that it is not necessary to know the exact location of prostate cancer foci. It is impossible to detect them all and remove them, but systemic therapies can affect cancer cells regardless of their location.

PSMA therapy is an alternative to chemotherapy. It is prescribed in the following cases:

  • Chemotherapy does not yield any result – the tumor does not respond to drug administration and continues to grow
  • Cytostatics are contraindicated for the patient for health reasons – he may not tolerate another course
  • The patient himself refuses to undergo chemotherapy because he no longer wants to endure side effects

Another field of Lu-177 application is treatment of the neuroendocrine tumors, particularly, gastro-, entero- and pancreatic ones (GEP tumors). GEP tumors have specific receptors for the somatostatin (somatostatin receptors, SSTR) on their cellular membrane. Thus, during the Lutetium therapy for neuroendocrine carcinoma specific peptides that resemble somatostatin’s structure are labeled with Lutetium compounds (typically these are Lu-DOTATATE and octreotate).

Due to the affinity between SSTR and Lu-labeled compounds, Lutetium-DOTATATE treatment acts on the GEP tumors selectively. It decreases radiation burden on the healthy tissues. In addition, Lutetium-DOTATATE therapy can be performed in patients with slightly impaired kidney function. Lutetium-177 octreotate therapy is another type of peptide receptor radionuclide therapy (PRRT).

How does Lutetium-177-PSMA therapy in Europe work?


Before the procedure the patient visits the doctor for clinical examination and review of the existing medical reports (e.g. PSMA PET CT). If a patient doesn’t have any medical reports, it is necessary to have a PSMA scan in Germany – this test reveals possible efficacy of the subsequent therapy. Blood tests are also carried out, so the doctor can be sure that the patient's liver and kidney functions are normal.

After this, the radiopharmaceutical is injected into the patient's vein slowly using a syringe. This is the whole procedure, actually. Additional drugs may be used to reduce the risk of complications and reduce side effects. The external cooling of the salivary glands with ice packs is carried out in order to prevent suppression of their work and xerostomia (dry mouth).

During the course of treatment, the man stays in a screened ward, as he is a source of beta-radiation for a while. Urine and stool become radioactive, so it is recommended to drink a lot of water and urinate frequently, flush the toilet 2-3 extra times, and wash the underclothes separately for up to 7 days. The patient is allowed to take personal belongings to the ward. They will not become radioactive and can be used in the future.

A day after the introduction of Lutetium-177 the patient will undergo the control scintigraphy. This is a follow-up examination, which allows for the evaluation of the treatment results. 10 days later, the person will come to the clinic again and undergo a repeated study. The scintigraphy demonstrates the number of bone metastases and their size.

Several sessions of Lutetium-177 treatment are usually carried out in order to achieve the long-lasting result. On average, the patient undergoes three treatment cycles. The recommended intervals between them are 8 weeks. Medical monitoring is provided through PET-CT, PSA blood test, and general clinical studies. The doctors also control liver, kidney, and bone marrow function.

Effectiveness of Lutetium-177-PSMA therapy in Europe


Lutetium-177 for cancer treatment is a relatively safe method. It does not cause irreversible complications. The doctors carefully monitor the condition of the patient and those for whom therapy can be harmful are not allowed to undergo it. If prostate cancer is treated using this therapy, the doctors carefully monitor that the damage to healthy tissues was minimal. To this end, the following measures are taken:

  • Patient examination prior to treatment to identify possible contraindications
  • Cooling of the salivary glands in the course of therapy in order to prevent accumulation of the radiopharmaceutical in them
  • In case of liver metastases, the patient may need bile duct stenting in order to prevent the development of obstructive jaundice due to edema and impaired bile outflow into the duodenum
  • Intravenous infusion of crystalloid solutions serves to protect kidneys
  • In case of side effects, symptomatic drugs are used to relieve them

Long-term benefit of Lutetium-177 on prostate cancer is still under investigation, but the current results are very promising. Treatment of the disease with Lutetium-177 can cause side effects. The most frequent of them are nausea, swelling of the oral mucosa, impaired swallowing and difficulty speaking. All these side effects are temporary and do not threaten life.

The complications may include liver or kidney dysfunction, as well as inhibition of the hematopoietic function of the red bone marrow. In order to timely identify the emerging complications, the patient constantly undergoes clinical and biochemical blood tests. These tests are conducted before starting prostate cancer treatment, as well as after each session.

As for the results of treatment, doctors notice significantly lower levels of PSA in the blood (which indicated lower disease activity), shrinkage of the primary tumor, control of metastases, including their disappearance. Having the full course of PSMA therapy with Lu-177 is connected with longer life expectancy and better quality of life.

What is the cost of Lutetium treatment in European hospitals?


It is always challenging to estimate the precise cost of treatment overseas, and therapy in Europe in particular, because preliminary calculations sometimes do not include costs for extra procedures or diagnostic tests that might be necessary later in the course of treatment. The pre-calculated cost of treatment will be modified up or down because, in actuality, the preliminary cost of treatment in Europe frequently differs from reality due to the peculiarities of the clinical case.

Hence, learning about the approximate costs of prostate cancer therapy in Europe in terms of specific treatments is the only option available. The cost of Lutetium-177 PSMA therapy for prostate cancer is between 22,700 EUR and 44,000 EUR. Please use the website's contact form if you would like to receive a customized offer with an estimated Lutetium-177 treatment cost.

Please do not hesitate to contact Booking Health if you have any questions. We'll schedule an appointment and provide you pricing advice for the entire course of therapy, including PSMA therapy with Lu-177 and other necessary options.

Treatment in European hospitals with Booking Health


The prostate cancer treatment with Lutetium is carried out in the best healthcare facilities abroad. Many patients go to Germany to get highly qualified and high-tech medical care for malignant tumors. Booking Health can arrange this for you. Our services and benefits include:

  • Organization of Lutetium-177-PSMA therapy in one of the best specialized clinics abroad
  • Affordable treatment cost, which will be up to 50% lower due to the exclusion of extra charges for foreign patients
  • Communication with the doctors of the clinic and its administration both prior to prostate cancer treatment start and after its completion
  • Preparation of the preliminary treatment program
  • Appointment at the dates convenient for the patient
  • Assistance in purchasing and shipping of medicines for continuing treatment in the native country
  • Control of invoices, treatment costs, return of unspent funds
  • Organization of additional diagnostic or therapeutic procedures in the clinic, if necessary

Booking Health provides high quality organizational services for over 15 years. Our employees will book airline tickets for you, choose the hotel closest to the medical facility, meet you at the airport and take you to the clinic by car. An interpreter and personal medical coordinator will help you cope with medical issues and feel comfortable while communicating with doctors.



The article was edited by medical experts, board certified doctors Dr. Nadezhda Ivanisova and Dr. Sergey Pashchenko. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!

Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.



National Library of Medicine

German Cancer Research Center

Cancer. Net